文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

异基因造血细胞移植后芦可替尼维持治疗慢性移植物抗宿主病发生率低

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.
PubMed 文献 · Blood · 2025-01-01

这项前瞻性、多中心、2期试验在减低强度异基因造血细胞移植后给予芦可替尼维持治疗,移植前入组78例、63例接受干预。1年无GVHD无复发生存率为70%,2年中重度cGVHD为16%,需全身治疗的cGVHD 1年为9.5%、2年为13%。

要点

  • 移植后30至100天开始芦可替尼,28天为一周期,最多24周期,中位起始日为+45天。
  • 主要终点1年无GVHD无复发生存率为70%。
  • 2年中重度cGVHD为16%,需全身治疗cGVHD 1年9.5%、2年13%。

核心结论

  • 移植后长期给予芦可替尼与临床显著慢性GVHD发生率低相关。
  • 将JAK抑制纳入GVHD预防策略需进一步研究。

研究设计与样本

  • 前瞻性、多中心、2期试验,移植前入组78例,63例接受干预。
  • 减低强度异基因造血细胞移植后给予芦可替尼维持治疗,GVHD预防为他克莫司联合甲氨蝶呤。
  • 芦可替尼于移植后+30至+100天开始,28天为一周期持续给药,最多24周期,中位起始日为+45天。
  • 试验注册号NCT03286530。

主要发现

  • 主要终点移植后1年无GVHD无复发生存率为70%。
  • 6个月时3至4级急性GVHD为4.8%,2年中重度cGVHD为16%。
  • 需全身治疗的cGVHD 1年为9.5%,2年为13%。
  • 2年总生存率为76%,无进展生存率为68%。
  • 最常见≥3级不良事件为中性粒细胞减少、血小板减少和贫血,7例发生≥3级感染事件。

局限性

  • 原文指出将JAK抑制纳入GVHD预防策略需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD (cGVHD) remain of high importance. In this prospective, multicenter, phase 2 trial, ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was administered as maintenance therapy after reduced-intensity allogeneic hematopoietic cell transplantation (HCT). GVHD prophylaxis consisted of tacrolimus and methotrexate. Ruxolitinib began between day +30 to 100 and was administered continuously in 28-day cycles for up to 24 cycles. Seventy-eight participants were enrolled before HCT; 63 participants received the intervention. The median start date of ruxolitinib after HCT was day +45. The most common grade ≥3 adverse events were neutropenia, thrombocytopenia, and anemia. Seven participants experienced grade ≥3 infectious events. GVHD-free, relapse-free survival at 1 year after HCT, the primary end point, was 70%. Grade 3 to 4 acute GVHD at 6 months was 4.8%, and moderate-severe cGVHD at 2 years was 16%. cGVHD requiring systemic therapy was 9.5% at 1 year and 13% at 2 years. Overall survival and progression-free survival at 2 years were 76% and 68%, respectively. Prolonged administration of ruxolitinib following HCT is associated with low rates of clinically significant cGVHD. The incorporation of JAK inhibition into GVHD prevention approaches warrants further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03286530.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. DeFilipp Z, Kim HT, Knight LW, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025. PMID: 40106768. doi:10.1182/blood.2024028005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。